Table 3 Sensitivity analysis by sequential omission of each individual study
From: Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis
Meta-analysis estimates, given the named study is omitted | ||
|---|---|---|
Study omitted | Hazard ratio for overall survival (95% CI) | Hazard ratio for progression-free survival (95% CI) |
Porrata et al. (2012a) [51] | 2.82 (1.61, 4.93) | 2.18 (1.33, 3.59) |
Porrata et al. (2012b) [52] | 2.25 (1.47, 3.43) | 2.06 (1.29, 3.29) |
Koh et al. (2015) [53] | 2.60 (1.57, 4.31) | – |
Tadmor et al. (2015) [54] | 3.12 (2.22, 4.37) | 2.66 (1.82, 3.88) |
Simon et al. (2016) [55] | 2.48 (1.53, 4.01) | 1.86 (1.34, 2.57) |
Vassilakopoulos et al. (2016) [56] | 2.66 (1.53, 4.63) | – |
Jakovic et al. (2016) [57] | 2.82 (1.61, 4.94) | – |
Romano et al. (2018) [58] | – | 2.37 (1.45, 3.90) |